$ALLO
Allogene Therapeutics, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019006991 Filed on March 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2017 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.06M
YoY Change 402.31%
% of Gross Profit
Research & Development $23.40M $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization $544.0K $0.00
YoY Change
% of Gross Profit
Operating Expenses $36.46M $2.000K
YoY Change 1303.97%
Operating Profit -$36.46M -$2.000K
YoY Change 1303.97%
Interest Expense $4.830M $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $4.825M $0.00
YoY Change
Pretax Income -$31.64M -$2.000K
YoY Change 1116.77%
Income Tax -$100.0K $0.00
% Of Pretax Income
Net Earnings -$31.59M -$2.000K
YoY Change 1116.25%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$324.6K
COMMON SHARES
Basic Shares Outstanding 121.5M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $470.4M
YoY Change
Cash & Equivalents $97.05M $0.00
Short-Term Investments $373.4M
Other Short-Term Assets $10.50M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $476.6M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $20.43M
YoY Change
Goodwill
YoY Change
Intangibles $603.0K
YoY Change
Long-Term Investments $214.6M
YoY Change
Other Assets $432.0K
YoY Change
Total Long-Term Assets $272.7M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $476.6M
Total Long-Term Assets $272.7M
Total Assets $749.4M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.98M
YoY Change
Accrued Expenses $14.30M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.27M $2.000K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $6.065M
YoY Change
Total Long-Term Liabilities $6.065M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $27.27M $2.000K
Total Long-Term Liabilities $6.065M
Total Liabilities $68.14M $2.000K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$243.1M -$23.00K
YoY Change
Common Stock $922.9M $26.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $681.2M -$2.000K
YoY Change
Total Liabilities & Shareholders Equity $749.4M
YoY Change

Cashflow Statement

Concept 2019 Q1 2017 Q4
OPERATING ACTIVITIES
Net Income -$31.59M -$2.000K
YoY Change 1116.25%
Depreciation, Depletion And Amortization $544.0K $0.00
YoY Change
Cash From Operating Activities -$30.26M $0.00
YoY Change -605220.0%
INVESTING ACTIVITIES
Capital Expenditures $10.42M $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $43.31M
YoY Change
Cash From Investing Activities $32.89M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $684.0K $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -$30.26M $0.00
Cash From Investing Activities $32.89M $0.00
Cash From Financing Activities $684.0K $0.00
Net Change In Cash $3.316M $0.00
YoY Change 66220.0%
FREE CASH FLOW
Cash From Operating Activities -$30.26M $0.00
Capital Expenditures $10.42M $0.00
Free Cash Flow -$40.68M $0.00
YoY Change -813680.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Entity Registrant Name
EntityRegistrantName
Allogene Therapeutics, Inc.
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Trading Symbol
TradingSymbol
ALLO
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
121482671
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001737287
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q2 dei Entity Public Float
EntityPublicFloat
0
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92432000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
366952000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8598000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
467982000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8595000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
754000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1299000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
244000
CY2018Q4 us-gaap Assets
Assets
773855000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12338000
CY2018Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
17121000
CY2017Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29459000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34456000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6776000
CY2018Q4 us-gaap Liabilities
Liabilities
70691000
CY2017Q4 us-gaap Liabilities
Liabilities
2000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
121000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2017Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
5000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
914265000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211528000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23000
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
261966000
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33015000
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-211505000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
306000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-211199000
CY2017Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.31
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28948386
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26249993
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
306000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
703164000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
773855000
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
47250000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121482671
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26249993
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121482671
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26249993
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151860000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40982000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2000
CY2018 us-gaap Operating Expenses
OperatingExpenses
192842000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
2000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-192842000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2000
CY2018 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
21211000
CY2018 us-gaap Interest Expense
InterestExpense
3358000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5789000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18780000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-211622000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
0
CY2017Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000
CY2017Q4 allo Notes Receivable From Common Shareholders
NotesReceivableFromCommonShareholders
-5000
CY2018 allo Stock Issued During Period Value Common Stock Issues
StockIssuedDuringPeriodValueCommonStockIssues
5000
CY2018 allo Subscriptions Receivable From Preferred Stockholders
SubscriptionsReceivableFromPreferredStockholders
150000000
CY2018 allo Stock Issued During Period Value Preferred Stock Issues
StockIssuedDuringPeriodValuePreferredStockIssues
150000000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
411052000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
141410000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
2000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18566000
CY2018 us-gaap Profit Loss
ProfitLoss
-211505000
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-2000
CY2018 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
109436000
CY2017Q4 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
18566000
CY2017Q4 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452000
CY2017Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1048000
CY2017Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1036000
CY2017Q4 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1832000
CY2017Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
0
CY2017Q4 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
0
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3358000
CY2017Q4 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
6000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12138000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93731000
CY2017Q4 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0
CY2017Q4 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8598000
CY2017Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
244000
CY2018 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
2098000
CY2017Q4 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
0
CY2018 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
411052000
CY2017Q4 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-632798000
CY2017Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8800000
CY2017Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0
CY2017Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
299281000
CY2017Q4 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
116842000
CY2017Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11370000
CY2017Q4 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
343689000
CY2017Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
771182000
CY2017Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
93731000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2017Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44653000
CY2017Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3234000
CY2017Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2018 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
2606000
CY2017Q4 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2018 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
19235000
CY2017Q4 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
649307000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
141410000
CY2017Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2018 allo Convertible Preferred Stock Issued In Asset Acquisition
ConvertiblePreferredStockIssuedInAssetAcquisition
111770000
CY2017Q4 allo Convertible Preferred Stock Issued In Asset Acquisition
ConvertiblePreferredStockIssuedInAssetAcquisition
0
CY2018 allo Property Plant Equipment And Other Assets Acquired In Asset Acquisition
PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
111770000
CY2017Q4 allo Property Plant Equipment And Other Assets Acquired In Asset Acquisition
PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
0
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
33015000
CY2017Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3182000
CY2017Q4 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2018 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
356000
CY2017Q4 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2018 us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
31000
CY2017Q4 us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit and other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions.&#160;As of December&#160;31, 2018, the Company has not experienced any credit losses in such accounts or investments.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is subject to a number of risks common for early-stage biopharmaceutical companies </font>industry including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities<font style="Background-color:#FFFFFF;">. </font></p>
CY2018Q3 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
5100000
CY2018 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-11-30
CY2017Q4 allo Start Up Cost
StartUpCost
2000000
CY2018Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
343300000
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3200000
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2018Q4 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
1-for-5.25
CY2018Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1905
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
721400000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
713709000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
743000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
320000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
714132000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
85214000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
366952000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
261966000
CY2018Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
714132000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
375625000
CY2018Q4 allo Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
240614000
CY2018Q4 allo Available For Sale Securities Debt Maturities Within Three Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue
36870000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
61023000
CY2018Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P3Y
CY2018 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2018Q4 allo Accrued Interest On Short Term Marketable Securities
AccruedInterestOnShortTermMarketableSecurities
3108000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2376000
CY2018Q4 allo Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2356000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
758000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9643000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1048000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000
CY2018Q4 allo Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7808000
CY2018Q4 allo Unvested Shares Liabilities Current
UnvestedSharesLiabilitiesCurrent
4590000
CY2018Q4 allo Accrued Compensation And Related Benefits Current
AccruedCompensationAndRelatedBenefitsCurrent
4111000
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2018 allo Shortterm Lease Rent Expense
ShorttermLeaseRentExpense
2600000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18566000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
612000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2000
CY2018Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
3258000
CY2018Q2 allo Discount Rate For Valuation
DiscountRateForValuation
0.165
CY2018Q3 allo Area Of New Office Building
AreaOfNewOfficeBuilding
68000
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P127M
CY2018Q3 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2029-02-28
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
531000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5020580
CY2018Q4 allo Deferred Tax Liabilities Right Of Use Leased
DeferredTaxLiabilitiesRightOfUseLeased
9239000
CY2018Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
118000
CY2018Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1000000
CY2018Q4 allo Area Of New Office Building
AreaOfNewOfficeBuilding
14943
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
CY2018Q4 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2029-02-28
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2018Q4 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
800000
CY2018Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2018Q4 allo Operating Leases Number Of Lease Agreements
OperatingLeasesNumberOfLeaseAgreements
2
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3602000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5653000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5834000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5942000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
39791000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
60822000
CY2018Q4 allo Operating Leases Future Minimum Payments Due Present Value Adjustment
OperatingLeasesFutureMinimumPaymentsDuePresentValueAdjustment
20107000
CY2018Q4 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
5942000
CY2018Q4 allo Operating Leases Future Minimum Payments Due Present Value
OperatingLeasesFutureMinimumPaymentsDuePresentValue
34773000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1900000
CY2018Q4 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
1600000
CY2018Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
120200000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
116800000
CY2018Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
120200000
CY2018Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
141400000
CY2018 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
21200000
CY2018Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3400000
CY2018Q2 allo Aggregate Purchase Price Shares Value
AggregatePurchasePriceSharesValue
300000000
CY2018Q3 us-gaap Temporary Equity Shares Subscribed But Unissued Subscriptions Receivable
TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable
150000000
CY2018 allo Modification Of Convertible Preferred Stock For Common Stock
ModificationOfConvertiblePreferredStockForCommonStock
26249993
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
59500000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2018Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
4600000
CY2018Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
6800000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
400000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-89000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-30000
CY2018 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-119000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-44441000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-10652000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3629000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
708000
CY2018 allo Income Tax Reconciliation Write Off Of In Process Research And Development
IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
5247000
CY2018 allo Income Tax Reconciliation Change In Fair Value Of Convertible Notes
IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
4454000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
41916000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
438000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16437000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1239000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
23086000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
952000
CY2018Q4 allo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
9730000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9888000
CY2018Q4 allo Deferred Tax Assets Net Of Deferred Tax Liabilities
DeferredTaxAssetsNetOfDeferredTaxLiabilities
41916000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
360000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-30509000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51804000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance Noncurrent
DeferredTaxAssetsValuationAllowanceNoncurrent
41916000
CY2018 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
41900000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-43497000
CY2018 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
100000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
920000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
920000
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31943612
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
2597000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
135012000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
22187000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
33046000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2597000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-134902000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-43.82
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.71
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37

Files In Submission

Name View Source Status
0001564590-19-006991-index-headers.html Edgar Link pending
0001564590-19-006991-index.html Edgar Link pending
0001564590-19-006991.txt Edgar Link pending
0001564590-19-006991-xbrl.zip Edgar Link pending
allo-10k_20181231.htm Edgar Link pending
allo-20181231.xml Edgar Link completed
allo-20181231.xsd Edgar Link pending
allo-20181231_cal.xml Edgar Link unprocessable
allo-20181231_def.xml Edgar Link unprocessable
allo-20181231_lab.xml Edgar Link unprocessable
allo-20181231_pre.xml Edgar Link unprocessable
allo-ex1017_446.htm Edgar Link pending
allo-ex1018_447.htm Edgar Link pending
allo-ex231_148.htm Edgar Link pending
allo-ex311_9.htm Edgar Link pending
allo-ex312_8.htm Edgar Link pending
allo-ex321_6.htm Edgar Link pending
allo-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmqf44qr50zb000001.jpg Edgar Link pending
gmqf44qr50zb000002.jpg Edgar Link pending
gnvfupfqwvxg000001.jpg Edgar Link pending
gnvfupfqwvxg000002.jpg Edgar Link pending
gnvfupfqwvxg000003.jpg Edgar Link pending
gnvfupfqwvxg000004.jpg Edgar Link pending
gnvfupfqwvxg000005.jpg Edgar Link pending
gnvfupfqwvxg000006.jpg Edgar Link pending
gnvfupfqwvxg000007.jpg Edgar Link pending
gw0h2zmlnqld000001.jpg Edgar Link pending
gw0h2zmlnqld000002.jpg Edgar Link pending
gw0h2zmlnqld000003.jpg Edgar Link pending
gw0h2zmlnqld000004.jpg Edgar Link pending
gw0h2zmlnqld000005.jpg Edgar Link pending
gw0h2zmlnqld000006.jpg Edgar Link pending
gw0h2zmlnqld000007.jpg Edgar Link pending
gw0h2zmlnqld000008.jpg Edgar Link pending
gw0h2zmlnqld000009.jpg Edgar Link pending
gw0h2zmlnqld000010.jpg Edgar Link pending
gw0h2zmlnqld000011.jpg Edgar Link pending
gw0h2zmlnqld000012.jpg Edgar Link pending
gw0h2zmlnqld000013.jpg Edgar Link pending
gw0h2zmlnqld000014.jpg Edgar Link pending
gw0h2zmlnqld000015.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending